ClinicalTrials.gg
CompletedNCT01114529ELEVATEUpdated May 30, 2017Results posted

Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients

A Phase 3 interventional study of Everolimus and Prograf or Neoral in Kidney Transplantation, sponsored by Novartis Pharmaceuticals. Completed at 77 sites in 21 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
828
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study was to determine whether an early Calcineurin Inhibitor (CNI) to everolimus conversion at 10-14 weeks post transplantation improves renal allograft function without compromising efficacy compared to standard CNI treatment in de novo renal allograft recipients. In addition, the study was designed to evaluate the impact of a CNI-free regimen on evolution of cardiovascular parameters in de novo renal allograft recipients

Read the detailed description

This was a 24-month, multi-center, randomized, open-label trial with two parallel arms in adult de novo renal allograft recipients. The study consisted of a run-in period from transplantation to Randomization and a treatment period from Randomization until Month 24. At baseline visit, patients were transplanted and entered the run-in period from transplantation (Baseline) to Randomization (week 10-14 post-transplantation). At Week 10-14, eligible patients were randomized into one of the 2 treatment arms: standard CNIs and Myfortic versus everolimus and Myfortic and entered the treatment period of the study from Randomization to Month 24. Patients in both arms received steroids as per center practice and in any caseat least 5 mg/Day. At Randomization, patients were stratified according to their renal allograft function and previous cardiovascular events. The main analysis was performed at Month 12 and the follow-up analysis was performed at Month 24.

02

Conditions studied

  • Kidney Transplantation

Keywords

  • de novo renal allograft recipients
  • renal allograft function
  • CNI-free regimen
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria at Baseline:

  • Male or female renal allograft recipients at least 18 years old.
  • Written .
  • Patient receiving a primary or secondary kidney transplant from a cadaveric or living unrelated-/related donor.
  • Cold ischemia time (CIT) \< 24 hours.
  • Negative pregnancy test for female patients.

Inclusion Criteria at Randomization:

  • Patients on CNI (TAC or CsA) + Myfortic + .
  • Serum creatinine \< 2.8 mg/dL (250 µmol/L) and an actual (MDRD4) ≥ 25 mL/min/1.73m exp2 (without renal replacement therapy).

Exclusion Criteria at Baseline:

Patients fulfilling any of the following criteria are not eligible for inclusion in this study:

  • Recipient of multiple organ transplants.
  • Recipient of ABO incompatible allograft or a positive cross-match.
  • Panel Reactive Antibodies (PRA) level ≥ 30 %.
  • Positive test for (HIV).
  • Patient receiving an allograft from a surface Antigen (HBsAg) or a Virus (HCV) positive donor.
  • HBsAg and/or a HCV positive patient with evidence of elevated LFTs (/AST levels ≥ 2.5 times ).
  • Severe restrictive or obstructive pulmonary disorders.
  • Patient with severe allergy requiring acute or chronic treatment or to any of the study drugs or similar drugs.
  • Severe hypercholesterolemia or hypertriglyceridemia.
  • Low count.
  • Low white blood cell count.
  • History of of any organ system

Exclusion Criteria at Randomization:

  • Graft loss.
  • Patient on renal replacement therapy.
  • Patient who experienced severe humoral and/or cellular rejection (BANFF ≥ IIb).
  • Patient with ≥ 2 episodes of AR or an AR episode that needed antibody treatment.
  • Patient with ongoing or currently treated AR (2 weeks prior to randomization).
  • Proteinuria > 1 g/day.
  • Patients with recurrence of Focal Segmental Glomerulosclerosis (FSGS).
  • Low platelet count; Low white blood cell count; Low ; Low .
  • Severe liver disease.
  • Systemic infection requiring continued therapy that would interfere with the objectives of the study.
  • Severe hypercholesterolemia or hypertriglyceridemia.
  • Patients with ongoing wound healing problems, infection requiring continued therapy.
  • Presence of intractable complications or side effects.
  • Patients on anticoagulants that prevents renal allograft .
  • Use of prohibited medication.
  • Use of immunosuppressive agents not utilized in the protocol.
  • Pregnant or nursing (lactating) women.
  • Women of not using a highly effective method of .
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
828 participants (actual)

Study arms

  • Experimental
    Everolimus

    Conversion from CNI to everolimus in combination with Myfortic and steroids

    Drug: Everolimus

  • Active comparator
    Calcineurin inhibitor, Prograf or Neoral

    Control arm: CNI continuation, either Prograf or Neoral in combination with Myfortic and steroids

    Drug: Prograf or Neoral

Interventions

  • Early CNI to everolimus conversion

    Also known as: Certican, Zortress, RAD001

  • DrugPrograf or Neoral

    Active CNI-based control (Prograf or Neoral)

    Also known as: Tacrolimus or Cyclosporine

06

What researchers measure

Primary outcomes

  1. Estimated Glomerular Filtration Rate (eGFR)

    Assessment of renal function by comparing change from randomization to Month 12 in eGFR (MDRD4) between treatment arms (Full analysis set). Renal function was assessed by estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. MDRD formula: GFR \[mL/min/1.73m˄2\] = 186.3\*(C˄-1.154)\*(A˄-0.203)\*G\*R. DEFINITIONS: C = serum concentration of creatinine \[mg/dL\]; A = age \[years\]; G = 0.742 when gender is female, otherwise G = 1; R = 1.21 when race is black, otherwise R = 1

    Time frame: Month 12

Secondary outcomes

  1. Incidence of Composite Efficacy Endpoint for Each Arm at Month 12 and Month 24

    Efficacy failure rate used the composite endpoint of: (1) treated biopsy-proven acute rejection (BPAR)\*, (2) graft loss\*\*, or (3) death . \*A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. \*\*Graft loss is defined as when the allograft was presumed lost on the day the participant started dialysis and was not able to subsequently be removed from dialysis or re-transplanted.

    Time frame: at 12 months and month 24 post-transplantation

  2. Change in Left Ventricular Mass Index (LVMi) From Randomization to Month 12 and Month 24

    Evolution of left ventricular mass and hypertrophy were evaluated by left ventricular mass index (LVMi) assessed by echocardiography. LVMi is derived using a standard formula from dimensional measurements on the echocardiogram. Analysis of covariance was applied with treatment, center (as a random effect), and donor type as factors and LVMi at Randomization as covariate.

    Time frame: Randomization, Month 12 and Month 24

  3. Comparison of Incidence Rates of Efficacy Endpoints Between Treatment Arms (Full Analysis Set - 24 Month Analysis)

    (treated BPAR ≥ IB, graft loss or death)A comparison of the incidence rates for the individual components of the composite efficacy endpoint between treatment arms

    Time frame: at 24 months post-transplantation

07

Results

Posted May 30, 2017

Participant flow

Full analysis set (24 month analysis)

Completed Study Medication at Month 24
Participant flow — Completed Study Medication at Month 24
MilestoneEverolimusStandard CNI (Tac)Standard CNI (CsA)
Started353231125
Completed22919093
Not completed1244132
Withdrew: Adverse event871817
Withdrew: Abnormal laboratory value(s)601
Withdrew: Abnormal test procedure result(s)301
Withdrew: Lack of efficacy212
Withdrew: Subject's no longer required drug111
Withdrew: Withdrawal by subject1882
Withdrew: Lost to follow-up142
Withdrew: Administrative problems212
Withdrew: Death212
Withdrew: Graft loss020
Withdrew: Protocol violation052
Withdrew: Missing200
Completed Study Phase at Month 24
Participant flow — Completed Study Phase at Month 24
MilestoneEverolimusStandard CNI (Tac)Standard CNI (CsA)
Started353231125
Completed313215111
Not completed401614
Withdrew: Withdrawal by subject1863
Withdrew: Lost to follow-up1057
Withdrew: Death854
Withdrew: Other200
Withdrew: Missing200

Outcome measures

PrimaryEstimated Glomerular Filtration Rate (eGFR)

Assessment of renal function by comparing change from randomization to Month 12 in eGFR (MDRD4) between treatment arms (Full analysis set). Renal function was assessed by estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. MDRD formula: GFR \[mL/min/1.73m˄2\] = 186.3\*(C˄-1.154)\*(A˄-0.203)\*G\*R. DEFINITIONS: C = serum concentration of creatinine \[mg/dL\]; A = age \[years\]; G = 0.742 when gender is female, otherwise G = 1; R = 1.21 when race is black, otherwise R = 1

Time frame:
Month 12
Reported as:
Mean · mL/min/1.73m^2
Estimated Glomerular Filtration Rate (eGFR)
mL/min/1.73m^2EverolimusStandard CNI (Tac)Standard CNI (CsA)
Estimated Glomerular Filtration Rate (eGFR)64.1 ± 22.3161.5 ± 19.8658.4 ± 19.62
SecondaryIncidence of Composite Efficacy Endpoint for Each Arm at Month 12 and Month 24

Efficacy failure rate used the composite endpoint of: (1) treated biopsy-proven acute rejection (BPAR)\*, (2) graft loss\*\*, or (3) death . \*A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. \*\*Graft loss is defined as when the allograft was presumed lost on the day the participant started dialysis and was not able to subsequently be removed from dialysis or re-transplanted.

Time frame:
at 12 months and month 24 post-transplantation
Reported as:
Number · Number of incidence
Incidence of Composite Efficacy Endpoint for Each Arm at Month 12 and Month 24
Number of incidenceEverolimusStandard CNI (Tac)Standard CNI (CsA)
Month 122148
Month 242788
SecondaryChange in Left Ventricular Mass Index (LVMi) From Randomization to Month 12 and Month 24

Evolution of left ventricular mass and hypertrophy were evaluated by left ventricular mass index (LVMi) assessed by echocardiography. LVMi is derived using a standard formula from dimensional measurements on the echocardiogram. Analysis of covariance was applied with treatment, center (as a random effect), and donor type as factors and LVMi at Randomization as covariate.

Time frame:
Randomization, Month 12 and Month 24
Reported as:
Mean · g/m^2.7
Change in Left Ventricular Mass Index (LVMi) From Randomization to Month 12 and Month 24
g/m^2.7EverolimusStandard CNI (Tac)Standard CNI (CsA)
Randomization50.30 ± 11.6251.08 ± 14.1151.13 ± 12.70
Month 1249.95 ± 12.6348.98 ± 14.6350.96 ± 13.00
Month 2446.66 ± 12.1945.63 ± 13.5047.91 ± 12.71
SecondaryComparison of Incidence Rates of Efficacy Endpoints Between Treatment Arms (Full Analysis Set - 24 Month Analysis)

(treated BPAR ≥ IB, graft loss or death)A comparison of the incidence rates for the individual components of the composite efficacy endpoint between treatment arms

Time frame:
at 24 months post-transplantation
Reported as:
Number · Number of incidence
Comparison of Incidence Rates of Efficacy Endpoints Between Treatment Arms (Full Analysis Set - 24 Month Analysis)
Number of incidenceEverolimusStandard CNI (Tac)Standard CNI (CsA)
Composite failure: tBPAR>=IB, graft loss, death2788
Composite tBPAR>=IB, graft loss, death, loss f/u351415
Composite of graft loss or Death1064
tBPAR>=IB1835
Graft loss422
Death854
Suspected Acute rejection612719
Subclinical Acute rejection000
Acute rejection (AR)521415
Treated Acute rejection (tAR)40914
biopsy proven acute rejection (BPAR)37813
treated biopsy proven acute rejection (tBPAR)32713
tBPAR=IA1638
tBPAR=IB1435
tBPAR=IIA301
tBPAR=IIB200
tBPAR=III000
Antibody tBPAR211
Antibody mediated rejection (AMR)1643

Adverse events

Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus—188/346 (54.3%)316/346 (91.3%)
Standard CNI (Tac)—118/238 (49.6%)216/238 (90.8%)
Standard CNI (CsA)—58/121 (47.9%)103/121 (85.1%)
Most frequent serious events
Showing 10 of 338
Most frequent serious events
EventEverolimusStandard CNI (Tac)Standard CNI (CsA)
Urinary tract infectionInfections and infestations25/34619/2388/121
Transplant rejectionImmune system disorders23/3465/2389/121
PyrexiaGeneral disorders25/3465/2384/121
Kidney transplant rejectionImmune system disorders19/3465/2388/121
Renal failure acuteRenal and urinary disorders7/3463/2387/121
Blood creatinine increasedInvestigations17/3466/2385/121
DiarrhoeaGastrointestinal disorders15/3469/2384/121
GastroenteritisInfections and infestations11/3469/2385/121
PneumoniaInfections and infestations14/3464/2385/121
PyelonephritisInfections and infestations13/3464/2385/121
Most frequent other events
Showing 10 of 30
Most frequent other events
EventEverolimusStandard CNI (Tac)Standard CNI (CsA)
DiarrhoeaGastrointestinal disorders79/34655/23813/121
Urinary tract infectionInfections and infestations75/34647/23818/121
PyrexiaGeneral disorders62/34620/23812/121
Oedema peripheralGeneral disorders60/34621/23813/121
Blood creatinine increasedInvestigations30/34624/23820/121
ProteinuriaRenal and urinary disorders52/34611/2382/121
LeukopeniaBlood and lymphatic system disorders48/34635/23811/121
AnaemiaBlood and lymphatic system disorders41/34621/2385/121
HypercholesterolaemiaMetabolism and nutrition disorders40/34615/2387/121
HypertensionVascular disorders35/34624/23812/121

Baseline characteristics

Full analysis set (FAS), 24 month analysis

Age, Continuous
Age, Continuous(years)EverolimusStandard CNI (Tac)Standard CNI (CsA)Total
Mean46.0 ± 14.447.3 ± 14.545.4 ± 15.646.2 ± 14.8
Sex: Female, Male
Sex: Female, Male(Participants)EverolimusStandard CNI (Tac)Standard CNI (CsA)Total
Female1117133215
Male24216092494
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)EverolimusStandard CNI (Tac)Standard CNI (CsA)Total
Caucasian246 ± 69.7173 ± 74.997 ± 77.6516
Black4 ± 1.15 ± 2.20 ± 09
Asian66 ± 18.741 ± 17.720 ± 16.0127
Native American1 ± 0.30 ± 0.00 ± 0.01
Pacific Islander0 ± 01 ± 0.41 ± 0.82
Other36 ± 10.211 ± 4.87 ± 5.654
08

Study locations

77 sites
  • Novartis Investigative Site
    Caba, Buenos Aires C1118AAT, Argentina
  • Novartis Investigative Site
    San Martin, Buenos Aires C1107BEA, Argentina
  • Novartis Investigative Site
    Resistencia, Chaco H3508AZP, Argentina
  • Novartis Investigative Site
    Cordoba, X5016JDA, Argentina
  • Novartis Investigative Site
    Cordoba, X5016KEH, Argentina
  • Novartis Investigative Site
    Cordoba, X5022CPU, Argentina
  • Novartis Investigative Site
    Santa Fe, S3000EPV, Argentina
  • Novartis Investigative Site
    Camperdown, New South Wales 2050, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Clayton, Victoria 3168, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3050, Australia
  • Novartis Investigative Site
    Linz, A-4010, Austria
  • Novartis Investigative Site
    Linz, A-4020, Austria
  • Novartis Investigative Site
    Wien, 1090, Austria
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Tartu, 51014, Estonia
  • Novartis Investigative Site
    Brest, 29200, France
  • Novartis Investigative Site
    Nice Cedex 1, 06602, France
  • Novartis Investigative Site
    Toulouse Cedex 4, 31054, France
  • Novartis Investigative Site
    Tours Cedex, 37044, France
  • Novartis Investigative Site
    Vandoeuvre Les Nancy, 54511, France
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Berlin, 12203, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Frankfurt am Main, 60596, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hannover Muenden, 34346, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Athens, GR 11527, Greece
  • Novartis Investigative Site
    Athens, GR-106 76, Greece
  • Novartis Investigative Site
    Patras, 265 00, Greece
  • Novartis Investigative Site
    Vishakhapatnam, Andhra Pradesh, India
  • Novartis Investigative Site
    New Delhi, Delhi 110017, India
  • Novartis Investigative Site
    Bangalore, Karnataka 560 055, India
  • Novartis Investigative Site
    Lucknow, Uttar Pradesh 226014, India
  • Novartis Investigative Site
    New Delhi, 110044, India
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Padova, PD 35128, Italy
  • Novartis Investigative Site
    Roma, RM 00144, Italy
  • Novartis Investigative Site
    Siena, SI 53100, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Riga, 1002, Latvia
  • Novartis Investigative Site
    Vilnius, LT-08661, Lithuania
  • Novartis Investigative Site
    Torreón, Coahuila 27250, Mexico
  • Novartis Investigative Site
    Mexico, Distrito Federal 14080, Mexico
  • Novartis Investigative Site
    Aguascalientes, 20230, Mexico
  • Novartis Investigative Site
    Veracruz, 91700, Mexico
  • Novartis Investigative Site
    Amsterdam, 1105 AZ, Netherlands
  • Novartis Investigative Site
    Groningen, 9713 GZ, Netherlands
  • Novartis Investigative Site
    Leiden, 2300 RC, Netherlands
  • Novartis Investigative Site
    Oslo, 0424, Norway
  • Novartis Investigative Site
    Carnaxide - Linda-A-Velha, Lisboa 2790-134, Portugal
  • Novartis Investigative Site
    Lisbon, 1069-166, Portugal
  • Novartis Investigative Site
    Porto, 4200-319, Portugal
  • Novartis Investigative Site
    Cluj-Napoca, Jud Cluj 400006, Romania
  • Novartis Investigative Site
    Krasnodar, 350086, Russian Federation
  • Novartis Investigative Site
    Moscow, 115446, Russian Federation
  • Novartis Investigative Site
    Moscow, 123182, Russian Federation
  • Novartis Investigative Site
    Nizhnii Novgorod, 603000, Russian Federation
  • Novartis Investigative Site
    Novosibirsk, 630087, Russian Federation
  • Novartis Investigative Site
    S.-Petersburg, 192242, Russian Federation
  • Novartis Investigative Site
    Samara, 443079, Russian Federation
  • Novartis Investigative Site
    Volzhskiy, 404120, Russian Federation
  • Novartis Investigative Site
    Malaga, Andalucia 29010, Spain
  • Novartis Investigative Site
    Santander, Cantabria 39008, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08003, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08036, Spain
  • Novartis Investigative Site
    Hospitalet de Llobregat, Cataluña 08907, Spain
  • Novartis Investigative Site
    A Coruña, Galicia 15006, Spain
  • Novartis Investigative Site
    Zaragoza, 50009, Spain
  • Novartis Investigative Site
    Khon Kaen, THA 40002, Thailand
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Antalya, 07000, Turkey
  • Novartis Investigative Site
    Büyükçekmece / Ýstanbul, 34520, Turkey
  • Novartis Investigative Site
    Fatih / Istanbul, 34098, Turkey
  • Novartis Investigative Site
    Istanbul, 34093, Turkey
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2010 to primary completion in Oct 2014, 50 months.

Results were first posted in May 2017, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2010
First posted
May 3, 2010
StartActual
Aug 9, 2010
Primary completionActual
Oct 30, 2014
CompletionActual
Oct 30, 2014
Results first posted
May 30, 2017
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01114529
Responsible party
Sponsor
First posted
May 3, 2010
Start date
Aug 9, 2010
Primary completion
Oct 30, 2014
Completion
Oct 30, 2014
Results posted
May 30, 2017
Last update
May 30, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion